Gilead's Bixlenvo Receives FDA Approval for Once-Daily HIV Treatment

The U.S. FDA has approved Gilead Sciences' Bixlenvo, a new once-daily single-tablet regimen for adults with HIV-1 who are virologically suppressed. This combination of bictegravir 75 mg and lenacapavir 50 mg offers a simpler treatment option, particularly benefiting patients who previously managed complex multi-tablet therapies due to resistance or tolerability issues, thereby improving adherence and quality of life.